AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Date:

Today marks an important step in turning the corner on the pandemic and getting things back to normal. Following the positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil, which showed the vaccine was highly effective in preventing COVID-19, we are confident that our united response, across the scientific community, industry, organisations, and governments, will make significant inroads in curbing the COVID-19 pandemic that has continued to claim thousands of lives every day in Africa and across the globe. We will continue to work hard to honour our commitment to make the vaccine available in a fair and equitable manner as rapidly as possible, following robust regulatory approval and meeting stringent efficacy and safety standards. It is a great day for innovation and for inclusion, an exciting moment for human health.

Barbara Nel Country President African Cluster: South Africa, Sub Saharan Africa, French Speaking Africa

Full AstraZeneca Regulatory News Service News Release available here (https://bit.ly/339VrKS).

 

SOURCE
AstraZeneca

Share post:

Subscribe

Popular

CBG records GHS1bn revenue in third quarter of 2024.

The Consolidated Bank Ghana Ltd. (CBG), has recorded GHS1...

Mahama failed to provide chalk, NPP is supplying laptops to students – Bawumia.

New Patriotic Party (NPP) flagbearer Dr. Mahamudu Bawumia has...

Project commissioning is not a ploy to attract votes—Oppong Nkrumah.

Housing Minister Kojo Oppong Nkrumah has said the recent...

Eat healthy and warm foods to avoid cholera –Dr. Adomako-Boateng.

Ghanaians have been advised to eat healthy and warm...

More like this
Related